| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — |
| Current Ratio | 10.04 | 9.84 | 12.26 | 9.13 | 15.92 | 8.77 |
| Quick Ratio | 10.04 | 9.84 | 12.26 | 9.13 | 15.92 | 8.77 |
| Debt / Equity | 0.13 | 0.11 | 0.16 | 0.13 | 0.04 | -0.02 |
| ROE | -38.30% | -38.17% | -39.48% | -58.95% | -26.89% | 89.19% |
| ROA | -31.44% | -32.17% | -31.63% | -47.15% | -24.48% | -81.44% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book Value / Share | 1.15 | 1.81 | 2.11 | 3.38 | 6.89 | -4.98 |
Erasca, Inc. is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product candidate is naporafenib, which is currently in pivotal Phase 3 trials (SEACRAFT-2) for patients with NRAS-mutated melanoma. Erasca's pipeline also includes ERAS-0015, a pan-RAS molecular glue designed to treat RAS-altered solid tumors; ERAS-4001, a pan-KRAS inhibitor for KRAS-altered solid tumors; and ERAS-12, an investigational EGFR biparatopic antibody for solid tumors. The company employs a modality-agnostic approach to targeting the RAS/MAPK signaling pathway, which is implicated in many human cancers. Erasca maintains a robust cash position to support its clinical development programs and has secured composition of matter patent protection for its key molecules extending through 2043. As a precision oncology specialist, Erasca addresses treatment opportunities in patient populations defined by specific genetic mutations in cancer-driving pathways.